The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018

scientific article published on 15 August 2019

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1186/S40425-019-0683-0
P932PMC publication ID6696687
P698PubMed publication ID31416487

P50authorAlberto MantovaniQ22069468
Gordon J. FreemanQ27088375
Paolo Antonio AsciertoQ89457677
Katerina PolitiQ91774071
Omid HamidQ94947567
Robert L FerrisQ38328358
Sandra DemariaQ38543969
Lisa H. ButterfieldQ41520723
P2093author name stringRoger S Lo
Paul Nathan
Igor Puzanov
P2860cites workNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceQ27853210
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotionQ27860475
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaQ29615443
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programQ30746423
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Q34557699
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Q36553576
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.Q36617328
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaQ36730827
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasiaQ37040899
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaQ37222679
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialQ38601785
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.Q38653551
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyQ38704192
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.Q38708831
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent ModelQ38821358
Elements of cancer immunity and the cancer-immune set pointQ39094764
Tumour-associated macrophages as treatment targets in oncology.Q39100693
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyQ39130451
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityQ40944056
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.Q42630391
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early AdaptationQ46418198
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.Q47270933
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerQ47389008
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity.Q47599849
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerQ47652834
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Q50001757
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaQ50207111
Understanding the tumor immune microenvironment (TIME) for effective therapy.Q52311744
A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer.Q52647887
Immune oncology, immune responsiveness and the theory of everything.Q55487467
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCQ57069952
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyQ57472982
Macrophage Checkpoint Blockade in Cancer - Back to the FutureQ58083703
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaQ58083758
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialQ58599459
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAQ58700455
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesQ62745707
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to ImmunotherapyQ89352753
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P433issue1
P921main subjectimmunotherapyQ1427096
P304page(s)221
P577publication date2019-08-15
P1433published inJournal for Immunotherapy of CancerQ27725163
P1476titleThe great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018
P478volume7